Truist Maintains Buy Rating on Revolution Medicines, $241 Target
Truist Securities maintained its Buy rating and $241 price target on Revolution Medicines. The target implies 35.4% upside from the Oct. 16 close of $177.96.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.